Diabetic Peripheral Neuropathy Market Report 2026

The diabetic peripheral neuropathy market size has grown strongly in recent years. It will grow from $3.83 billion in 2025 to $4.18 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to high incidence of diabetic nerve damage, delayed clinical intervention, limited awareness of early symptoms, dependence on analgesics, increasing diabetes duration.

The diabetic peripheral neuropathy market size is expected to see strong growth in the next few years. It will grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to improved screening technologies, expansion of specialty care centers, development of novel pain therapies, increased patient education, rising elderly diabetic population. Major trends in the forecast period include growing demand for peripheral neuropathy therapies, increased focus on early sensory loss detection, expansion of combination pain management treatments, rising adoption of long-term symptom control therapies, increased patient screening and monitoring.

The rise in obesity-related health issues is expected to drive the growth of the diabetic peripheral neuropathy market in the coming years. Obesity is a medical condition marked by excessive body fat accumulation that can impair health and increase the risk of multiple chronic diseases. The growing burden of obesity-related health issues is linked to lifestyle changes, increased disease awareness, and a rising demand for preventive and therapeutic solutions, which together are increasing healthcare utilization. Diabetic peripheral neuropathy management plays a role in addressing obesity-related complications by providing insights into nerve damage associated with metabolic conditions and supporting targeted interventions that improve patient well-being and quality of life. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 23 states reported adult obesity prevalence rates of 35% or higher in 2023, and all 50 states recorded obesity rates of at least 20%. Therefore, the increase in obesity-related health issues is contributing to the growth of the diabetic peripheral neuropathy market.

Major companies operating in the diabetic peripheral neuropathy market are emphasizing technological advancements, such as NaV1.8 pain signal inhibitors, to offer patients effective non-opioid treatment options that enhance pain control and overall quality of life. NaV1.8 pain signal inhibitors are specialized therapies that block the NaV1.8 sodium channel, a critical mediator of pain transmission in sensory neurons, enabling relief from acute and neuropathic pain without the use of opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotechnology company, announced progress in its suzetrigine pain program, including the initiation of a Phase 3 pivotal trial for the treatment of pain associated with diabetic peripheral neuropathy. Suzetrigine, a selective NaV1.8 inhibitor, demonstrated encouraging results in earlier studies and received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for diabetic peripheral neuropathy pain management.

In December 2024, ElectroCore Inc., a US-based medical technology company, acquired NeuroMetrix Inc. for $26 million. Through this acquisition, ElectroCore aims to broaden its bioelectronic health and wellness portfolio by integrating NeuroMetrix’s Quell platform. This strategic transaction is intended to expand non-invasive, technology-driven solutions for managing chronic pain and conditions such as diabetic peripheral neuropathy, while strengthening technological capabilities and extending market reach. NeuroMetrix Inc. is a US-based healthcare company that develops and markets products for the diagnosis and treatment of diabetic peripheral neuropathy.

Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., NeuroMetrix Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca plc., Bayer AG., UCB SA., Regeneron Pharmaceuticals Inc., Roche., Sanofi S.A., Amgen Inc., Lexicon Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd.

North America was the largest region in the diabetic peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic peripheral neuropathy market by increasing costs of imported pain medications, diagnostic equipment, and nerve assessment devices. Hospitals and neurology clinics in North America and Europe are most affected due to reliance on imported therapies, while Asia-Pacific faces higher diagnostic infrastructure costs. These tariffs raise treatment expenses. However, they are also encouraging domestic pharmaceutical manufacturing and localized diagnostic device production.

The diabetic peripheral neuropathy market research report is one of a series of new reports that provides diabetic peripheral neuropathy market statistics, including diabetic peripheral neuropathy industry global market size, regional shares, competitors with a diabetic peripheral neuropathy market share, detailed diabetic peripheral neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic peripheral neuropathy industry. This diabetic peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic peripheral neuropathy (DPN) is a nerve disorder resulting from prolonged elevated blood glucose levels in individuals with diabetes, causing nerve damage mainly in the legs, feet, arms, and hands. This condition develops when long-term high blood sugar damages nerves and blood vessels, leading to impaired nerve function and reduced blood flow to the affected areas.

The main types of diabetic peripheral neuropathy include type 2 diabetic peripheral neuropathy and type 1 diabetic peripheral neuropathy. Type 2 diabetic peripheral neuropathy is a nerve damage condition associated with sustained high blood sugar levels in type 2 diabetes, resulting in symptoms such as pain, numbness, and tingling, particularly in the feet and hands. Treatment options involve pain management medications and emerging gene therapies, while therapeutic approaches include the use of antidepressants and anticonvulsants. The patient population affected by diabetic peripheral neuropathy primarily consists of adult and elderly individuals.

The diabetic peripheral neuropathy market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical treatment services, and physical and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic peripheral neuropathy market also includes sales of pharmaceuticals, medical devices, nutritional supplements, and physical therapy tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.